Estimation of benefits, burden, and harms of colorectal cancer screening strategies: Modeling study for the US preventive services Task Force

JAMA - Journal of the American Medical Association

Volumn 315, Issue 23, 2016, Pages 2595-2609

  Knudsen, Amy B ^a   Zauber, Ann G ^b   Rutter, Carolyn M ^c   Naber, Steffie K ^d   Doria Rose, V Paul ^e   Pabiniak, Chester ^f   Johanson, Colden ^a,h   Fischer, Sara E ^b   Lansdorp Vogelaar, Iris ^d   Kuntz, Karen M ^g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c RAND CORPORATION   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e NATIONAL CANCER INSTITUTE   (United States)

^f GROUP HEALTH RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h OPTUM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; COHORT ANALYSIS; COLONOSCOPY; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; DIGESTIVE SYSTEM PERFORATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; IMMUNOCHEMISTRY; OCCULT BLOOD TEST; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; UNITED STATES; VERY ELDERLY; ADENOMA; ADVERSE EFFECTS; ADVISORY COMMITTEE; AGE; CHEMISTRY; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; EARLY CANCER DIAGNOSIS; FECES; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OCCULT BLOOD; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL; TIME FACTOR;

DNA;

ADENOMA; ADULT; ADVISORY COMMITTEES; AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; COLONOGRAPHY, COMPUTED TOMOGRAPHIC; COLONOSCOPY; COLORECTAL NEOPLASMS; DNA; EARLY DETECTION OF CANCER; FECES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MODELS, THEORETICAL; OCCULT BLOOD; PREVENTIVE HEALTH SERVICES; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; TIME FACTORS; UNITED STATES;

EID: 84975688690     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.6828     Document Type: Article

References (70)

1. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood: Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328(19):1365-1371.
2. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348(9040):1472-1477.
3. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348(9040):1467-1471.
4. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369(12):1106-1114.
5. Atkin WS, Edwards R, Kralj-Hans I, et al; UK Flexible Sigmoidoscopy Trial Investigators. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375 (9726):1624-1633.
6. Segnan N, Armaroli P, Bonelli L, et al; SCORE Working Group. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial: SCORE. J Natl Cancer Inst. 2011;103(17):1310-1322.
7. Schoen RE, Pinsky PF, Weissfeld JL, et al; PLCO Project Team. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366(25):2345-2357.
8. Holme Ø, Løberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. 2014;312(6):606-615.
9. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the US Preventive Services Task Force. Ann Intern Med. 2008;149(9): 659-669.
10. van Hees F, Habbema JD, Meester RG, Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG. Should colorectal cancer screening be considered in elderly persons without previous screening? a cost-effectiveness analysis. Ann Intern Med. 2014;160(11):750-759.
11. Rutter CM, Knudsen AB, Marsh TL, et al. Validation of models used to inform colorectal cancer screening guidelines: accuracy and implications. Med Decis Making. 2016;36(5):604-614.
12. Zauber A, Knudsen A, Rutter CM, Lansdorp-Vogelaar I, Kuntz KM. Evaluating the Benefits and Harms of Colorectal Cancer Screening Strategies: A Collaborative Modeling Approach. Rockville, MD: Agency for Healthcare Research and Quality; 2015. AHRQ publication 14-05203-EF-2.
13. Cancer Intervention and Surveillance Modeling Network (CISNET) Model Registry. National Cancer Institute. https://resources.cisnet.cancer.gov/registry. Accessed May 25, 2016.
14. Clark JC, Collan Y, Eide TJ, et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer. 1985;36(2):179-186.
15. Blatt L. Polyps of the colon and rectum: incidence and distribution. Dis Colon Rectum. 1961; 4(4):277-282.
16. Vatn MH, Stalsberg H. The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer. 1982;49(4):819-825.
17. Jass JR, Young PJ, Robinson EM. Predictors of presence, multiplicity, size and dysplasia of colorectal adenomas: a necropsy study in New Zealand. Gut. 1992;33(11):1508-1514.
18. Johannsen LG, Momsen O, Jacobsen NO. Polyps of the large intestine in Aarhus, Denmark: an autopsy study. Scand J Gastroenterol. 1989;24(7): 799-806.
19. Bombi JA. Polyps of the colon in Barcelona, Spain: an autopsy study. Cancer. 1988;61(7):1472-1476.
20. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut. 1982;23(10):835-842.
21. Rickert RR, Auerbach O, Garfinkel L, Hammond EC, Frasca JM. Adenomatous lesions of the large bowel: an autopsy survey. Cancer. 1979;43(5):1847-1857.
22. Chapman I. Adenomatous polypi of large intestine: incidence and distribution. Ann Surg. 1963;157(2):223-226.
23. Arminski TC, McLean DW. Incidence and distribution of adenomatous polyps of the colon and rectum based on 1,000 autopsy examinations. Dis Colon Rectum. 1964;7(4):249-261.
24. ∗Stat Database: Incidence-SEER 9 Regs Public-Use, Nov 2003 Sub (1973-2001). Surveillance, Epidemiology, and End Results (SEER) Program. Updated released April 2004, based on the November 2003 submission. http://www.seer.cancer.gov. Accessed May 25, 2016.
25. Life tables. National Center for Health Statistics. http://www.cdc.gov/nchs/products/life-tables.htm. Accessed May 25, 2016.
26. Rutter CM, Johnson EA, Feuer EJ, Knudsen AB, Kuntz KM, Schrag D. Secular trends in colon and rectal cancer relative survival. J Natl Cancer Inst. 2013;105(23):1806-1813.
27. Schroy PC III, Coe A, Chen CA, O'Brien MJ, Heeren TC. Prevalence of advanced colorectal neoplasia in white and black patients undergoing screening colonoscopy in a safety-net hospital. Ann Intern Med. 2013;159(1):13-20.
28. van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol. 2006;101(2):343-350.
29. Johnson CD, Chen MH, Toledano AY, et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med. 2008;359 (12):1207-1217.
30. van Hees F, Zauber AG, Klabunde CN, Goede SL, Lansdorp-Vogelaar I, van Ballegooijen M. The appropriateness of more intensive colonoscopy screening than recommended in Medicare beneficiaries: a modeling study. JAMA Intern Med. 2014;174(10):1568-1576.
31. Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009;150 (12):849-857, W152.
32. Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst. 2003; 95(3):230-236.
33. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.
34. Lin JS, Piper M, Perdue LA, et al. Screening for Colorectal Cancer: An Updated Systematic Review for the US Preventive Services Task Force: Evidence Synthesis No. 135. Rockville, MD: Agency for Healthcare Research and Quality; 2016. AHRQ publication 14-05203-EF-1.
35. Levi Z, Birkenfeld S, Vilkin A, et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate: a prospective, controlled, feasibility study. Int J Cancer. 2011;128(10):2415-2424.
36. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996; 334(3):155-159.
37. Weissfeld JL, Schoen RE, Pinsky PF, et al; PLCO Project Team. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst. 2005;97(13):989-997.
38. Atkin WS, Cook CF, Cuzick J, Edwards R, Northover JM, Wardle J; UK Flexible Sigmoidoscopy Screening Trial Investigators. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet. 2002;359(9314):1291-1300.
39. Painter J, Saunders DB, Bell GD, Williams CB, Pitt R, Bladen J. Depth of insertion at flexible sigmoidoscopy: implications for colorectal cancer screening and instrument design. Endoscopy. 1999; 31(3):227-231.
40. Mandelblatt JS, Cronin KA, Bailey S, et al; Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10): 738-747.
41. Mandelblatt JS, Stout NK, Schechter CB, et al. Collaborative modeling of the benefits and harms associated with different US breast cancer screening strategies. Ann Intern Med. 2016;164(4): 215-225.
42. de Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the US Preventive Services Task Force. Ann Intern Med. 2014;160(5):311-320.
43. Kulasingam SL, Havrilesky L, Ghebre R, Myers ER. Screening for Cervical Cancer: A Decision Analysis for the US Preventive Services Task Force: Evidence Syntheses, No. 86s. Rockville, MD: Agency for Healthcare Research and Quality; 2011. AHRQ report 11-05157-EF-1.
44. Kulasingam SL, Havrilesky LJ, Ghebre R, Myers ER. Screening for cervical cancer: a modeling study for the US Preventive Services Task Force. J Low Genit Tract Dis. 2013;17(2):193-202.
45. Mark DH. Visualizing cost-effectiveness analysis. JAMA. 2002;287(18):2428-2429.
46. Owens DK, Qaseem A, Chou R, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Ann Intern Med. 2011;154(3):174-180.
47. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(9):627-637.
48. Pickhardt PJ, Taylor AJ, Kim DH, Reichelderfer M, Gopal DV, Pfau PR. Screening for colorectal neoplasia with CT colonography: initial experience from the 1st year of coverage by third-party payers. Radiology. 2006;241(2):417-425.
49. Rutter CM, Yu O, Miglioretti DL. A hierarchical non-homogenous Poisson model for meta-analysis of adenoma counts. Stat Med. 2007;26(1):98-109.
50. Decision memo for screening for colorectal cancer: stool DNA testing (CAG-00440N). Centers for Medicare & Medicaid Services. http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=277. Accessed May 25, 2016.
51. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the US Preventive Services Task Force. Ann Intern Med. 2008;149(9):638-658.
52. Klabunde CN, Cronin KA, Breen N, Waldron WR, Ambs AH, Nadel MR. Trends in colorectal cancer test use among vulnerable populations in the United States. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1611-1621.
53. Pickhardt PJ. CT colonography for population screening: ready for prime time? Dig Dis Sci. 2015; 60(3):647-659.
54. Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, et al. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Making. 2011;31(4):530-539.
55. Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med. 2016;164(7):456-463.
56. Wilschut JA, Steyerberg EW, van Leerdam ME, Lansdorp-Vogelaar I, Habbema JD, van Ballegooijen M. How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer? Cancer. 2011;117 (18):4166-4174.
57. Lansdorp-Vogelaar I, Gulati R, Mariotto AB, et al. Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med. 2014;161(2):104-112.
58. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107(9):1315-1329.
59. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011;42(1):1-10.
60. Lakoff J, Paszat LF, Saskin R, Rabeneck L. Risk of developing proximal versus distal colorectal cancer after a negative colonoscopy: a population-based study. Clin Gastroenterol Hepatol. 2008;6(10):1117-1121.
61. Singh H, Turner D, Xue L, Targownik LE, Bernstein CN. Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA. 2006;295(20):2366-2373.
62. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150(1):1-8.
63. Singh H, Nugent Z, Demers AA, Kliewer EV, Mahmud SM, Bernstein CN. The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology. 2010;139 (4):1128-1137.
64. Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst. 2010; 102(2):89-95.
65. Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med. 2011;154(1):22-30.
66. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369(12):1095-1105.
67. Doubeni CA, Weinmann S, Adams K, et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med. 2013;158(5 Pt 1):312-320.
68. Baxter NN, Warren JL, Barrett MJ, Stukel TA, Doria-Rose VP. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol. 2012;30(21):2664-2669.
69. Ness RM, Holmes AM, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol. 1999;94(6):1650-1657.
70. Jones RM, Woolf SH, Cunningham TD, et al. The relative importance of patient-reported barriers to colorectal cancer screening. Am J Prev Med. 2010;38(5):499-507.